enterococci

Vulpinic Acid (Pulvinic acid methyl ester) 是地衣代谢物，可降低人脐静脉内皮细胞 (HUVEC) 中 H2O2诱导的ROS，氧化应激和氧化应激相关损伤，可作用于厌氧菌、葡萄球菌及肠球菌。它对脉粥样硬化的研究具有潜在的价值。

Antibacterial compound 2 是一种有效的抗菌剂，对许多人类兽医病原体有效，对多重耐药葡萄球菌、肠球菌和链球菌，以及厌氧菌有抑制作用。

Vancomycin hydrochloride (Vancomycin HCl) 是一种糖肽类抗生素,靶点是细菌细胞壁合成中的肽聚糖 (Peptidoglycan)。Vancomycin hydrochloride主要用于治疗严重的革兰阳性菌感染。

AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin i

MRSA/VRE-IN-1 (Compound 3e) 是一种抑制剂，专门针对耐甲氧西林金黄色葡萄球菌 (MRSA) 和耐万古霉素肠球菌 (VRE)。该化合物对VRE的MIC/MBC值分别为3.6/7.3 µM，对MRSA的MIC/MBC值为7.3/14.6 µM。MRSA/VRE-IN-1 可用于抗感染领域的研究。

Adicillin is a penicillin antibiotic that works against vancomycin-resistant enterococci.

Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

Kocurin is a thiazolyl peptide originally isolated fromK. palustrisand has antibiotic activity.1It is active against methicillin-resistantS. aureus(MRSA; MIC = 0.25 μg ml), as well asB. subtilisandE. faeciumin a solid agar test when used at a concentration of 8 μg ml. Kocurin is also active againstE. faecium,E. faecalis,S. epidermidis, and clinical isolates of vancomycin-resistant enterococci (MICs = 0.004-1.025 μg ml).2In vivo, kocurin (2.5, 5, and 10 mg ml) increases survival in a mouse model ofE. faecium-induced septicemia. It decreases the number of colony forming units (CFUs) in a mouse model of MRSA lung infection. 1.Martin, J., da S. Sousa, T., Crespo, G., et al.Kocurin, the true structure of PM181104, an anti-methicillin-resistant Staphylococcus aureus (MRSA) thiazolyl peptide from the marine-derived bacterium Kocuria palustrisMar. Drugs11(2)387-398(2013) 2.Mahajan, G., Thomas, B., Parab, R., et al.In vitro and in vivo activities of antibiotic PM181104Antimicrob. Agents Chemother.57(11)5315-5319(2013)

Platencin is a natural, broad spectrum Gram-positive antibiotic isolated from S. platensis, which is also the source of platensimycin . Platencin inhibits two key enzymes in bacterial fatty acid synthesis, β-ketoacyl-ACP synthases II and III (FabF and FabH, respectively), unlike platensimycin which only targets FabF. The IC50 values for platencin against FabF and FabH are 1.95 and 3.91 μg ml, respectively. It does not exhibit cross-resistance to antibiotic resistant bacterial strains, including methicillin-resistant S. aureus, vancomycin-intermediate S. aureus, and vancomycin-resistant Enterococci. For these reasons, platencin has potential applications in fighting antibiotic resistant bacteria.

Cefaloglycin（Cephaloglycin）是一种β-内酰胺类（β-lactam）口服活性头孢菌素类抗生素，具有肾毒性和抗菌活性。该药物对革兰氏阳性球菌（除肠球菌外）有效，同时对线粒体底物摄取及呼吸具有毒性。

Nemonoxacin (TG-873870) 是一种可口服的非氟化喹诺酮类抗生素，具有广谱的抗菌活性，抑制葡萄球菌、链球菌和肠球菌、淋病奈瑟菌和流感嗜血杆菌均。Nemonoxacin 可用于研究细菌感染和社区获得性肺炎。

6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) 在抗菌领域展现出显著效果，特别是对耐甲氧西林Staphylococcus aureus (MRSA)和Vancomycin enterococci (VRE)。该化合物能有效干扰细菌细胞膜的结构和功能，进而影响MRSA的代谢过程。除此之外，6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid 还具备抗炎及促进小鼠血管生成的特性，显示其在抗感染治疗中的潜力。

Epicorazine B 在革兰氏阳性菌中表现出活性，包括耐甲氧西林金黄色葡萄球菌（MRSA）和耐万古霉素肠球菌（VRE），其最低抑菌浓度（MIC）为 12.5-25 μg/mL。Epicorazine B 还对白色念珠菌有效，MIC 为 25 μg/mL。

Chloropolysporin C 具有强效的抗革兰氏阳性菌活性，涵盖耐甲氧西林金黄色葡萄球菌（MRSA）和肠球菌。

Diperamycin 对革兰氏阳性菌（包括肠球菌和 MRSA）表现出活性，MIC 为 0.10-0.20 μg/mL。同时，它对 L1210、P388、LS-180、KB、HeLaS3、Meth A 和 B16-BL6 的活性有显著抑制作用，IC50 为 0.009-0.098 μg/mL。

8-Epidiosbulbin E acetate 是从 Dioscorea bulbifera L. 中发现的丰富呋喃类化合物，具有对多重耐药菌广谱的质粒消除活性，可用于诱导小鼠肝损伤模型。

Glyasperin C acts as a partial estrogen antagonist, it shows tyrosinase inhibitory activity (IC (50) = 0.13 + - 0.01 microg mL), it could be a promising candidate in the design of skin-whitening agents. Glyasperin C shows potent anti-vancomycin-resistant

Chloropolysporin B 具备显著的抗革兰氏阳性菌特性，靶向包括耐甲氧西林金黄色葡萄球菌（MRSA）及肠球菌等。

Epicorazine A 对革兰氏阳性菌表现出活性，包括耐甲氧西林金黄色葡萄球菌 (MRSA) 和耐万古霉素肠球菌 (VRE)，其最低抑菌浓度 (MIC) 为 12.5-25 μg/mL。此外，Epicorazine A 对白色念珠菌的作用，MIC 为 25 μg/mL。